|
GSK PLC on Tuesday said interim results from the first part of its Ruby phase 3 clinical trial of its dostarlimab treatment in patients with primary advanced or recurrent endometrial cancer have shown positive results. The Brentford, England-based pharmaceutical company said the results indicated a ‘statistically significant and clinically meaningful’ improvement in progression free survival in patients treated with dostarlimab alongside carboplatin-paclitaxel, compared to those treated with a placebo. The company said there was a 72% reduction in the risk of disease progression and death observed in patients with high microsatellite instability mismatch repair deficient tumours, and a 36% reduction in the overall population. Dostarlimab, sold under the brand name Jemperli, is a programmed death recepter-1-blocking antibody, which increases the body’s ability to fight cancer cells. The company noted that there was also a ‘clinically meaningful’ overall survival trend in patients receiving dostarlimab with chemotherapy, followed by dostarlimab. GSK added that overall survival follow-up continues, and it has planned further analysis. GSK said it has planned regulatory submissions for the drug for the first half of 2023. Hesham Abdullah, senior vice president and global head of oncology development, said: ‘These positive results from the RUBY trial bring us one step closer to addressing the significant unmet needs of endometrial cancer patients and add to the growing body of evidence on dostarlimab, strengthening our belief in its potential to transform cancer treatment as a backbone immuno-oncology therapy.’ GSK shares rose 0.4% to 1,429.20 pence each in London on Tuesday morning. Copyright 2023 Alliance News Ltd. All Rights Reserved.
|
